Imagine a smart filter that catches liver disease long before it becomes dangerous, without needing a painful needle biopsy. It uses AI and blood tests to spot high-risk people and gives them a personalized plan for diet and exercise. Think of it as a high-tech early warning system for the liver.
Liver biopsies are invasive and risky, leading to underdiagnosis of MASH. There is a critical need for non-invasive, scalable screening tools to identify high-risk patients early.
An AI-based diagnostic platform and a set of validated lifestyle questionnaires for primary care use.
If you are a diagnostic kit manufacturer dealing with the lack of non-invasive liver tests — this project developed a platform testing multi-OMICs biomarkers that provides an alternative to liver biopsies. This allows for safer, faster screening of 10,000 high-risk patients.
If you are an AI software provider dealing with low accuracy in disease stratification — this project developed AI-based decision support tools. These tools use biomarker combinations to improve the detection of MASH patients at the primary care level.
If you are a drug developer dealing with difficulty finding qualified patients for clinical trials — this project developed a screening platform across 12 European Centers of Excellence. This creates a streamlined way to identify and characterize high-risk patients with obesity or diabetes.
Based on available project data, specific pricing or cost details are not provided, though the project investigates economic barriers to future adoption.
Yes, the project aims to create a sustainable and scalable platform currently being rolled out across 12 clinical sites with a target of 10,000 screened patients.
Based on available project data, specific licensing terms are not mentioned, but the consortium includes 12 industry partners, including 7 SMEs, suggesting a commercial focus.
The project runs from December 2023 to November 2027, with the first patient already screened and a pilot platform already tested at Amsterdam UMC.
The platform is designed for use at the primary care level and is being tested in 12 European Centers of Excellence to ensure it fits into clinical workflows.
The consortium is heavily geared toward commercialization, featuring a 35% industry ratio with 12 industrial partners, including 7 SMEs. This blend of 10 universities and 7 research institutes across 14 countries ensures that the AI tools and biomarkers are validated in diverse clinical settings while remaining market-oriented.
Contact Universitaire Medisch Centrum Utrecht
Contact us to explore licensing opportunities for the AI-based MASH screening tools.
